Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination
We report the case of a 19-year-old male who complained of myalgia, muscle weakness, and darkened urine two days after receiving his Ad26.COV2.S (Johnson & Johnson, New Brunswick, New Jersey, United States) COVID-19 vaccination. Blood examination revealed an increased creatine kinase (CK) level,...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/9/956 |
| _version_ | 1797517035195858944 |
|---|---|
| author | Georg Gelbenegger Filippo Cacioppo Christa Firbas Bernd Jilma |
| author_facet | Georg Gelbenegger Filippo Cacioppo Christa Firbas Bernd Jilma |
| author_sort | Georg Gelbenegger |
| collection | DOAJ |
| description | We report the case of a 19-year-old male who complained of myalgia, muscle weakness, and darkened urine two days after receiving his Ad26.COV2.S (Johnson & Johnson, New Brunswick, New Jersey, United States) COVID-19 vaccination. Blood examination revealed an increased creatine kinase (CK) level, and his urinary dipstick tested positive for blood, indicative of acute rhabdomyolysis. Serum creatinine levels were normal. Rhabdomyolysis due to strenuous physical activity was ruled out and further diagnostics excluded an autoimmune cause. Under repeated treatment with intravenous fluid resuscitation (outpatient treatment), his symptoms resolved and peak CK levels of 44,180 U/L returned to almost normal levels within two weeks. Rhabdomyolysis is a rare, potentially fatal vaccine-induced reaction. Further research is needed to better understand the underlying pathomechanism and to investigate whether subcutaneous injection of vaccines may be able to prevent rhabdomyolysis. |
| first_indexed | 2024-03-10T07:10:01Z |
| format | Article |
| id | doaj.art-d161fc09609040a6a58f80e0cbe66342 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T07:10:01Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-d161fc09609040a6a58f80e0cbe663422023-11-22T15:34:00ZengMDPI AGVaccines2076-393X2021-08-019995610.3390/vaccines9090956Rhabdomyolysis Following Ad26.COV2.S COVID-19 VaccinationGeorg Gelbenegger0Filippo Cacioppo1Christa Firbas2Bernd Jilma3Department of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Emergency Medicine, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Clinical Pharmacology, Medical University of Vienna, 1090 Vienna, AustriaWe report the case of a 19-year-old male who complained of myalgia, muscle weakness, and darkened urine two days after receiving his Ad26.COV2.S (Johnson & Johnson, New Brunswick, New Jersey, United States) COVID-19 vaccination. Blood examination revealed an increased creatine kinase (CK) level, and his urinary dipstick tested positive for blood, indicative of acute rhabdomyolysis. Serum creatinine levels were normal. Rhabdomyolysis due to strenuous physical activity was ruled out and further diagnostics excluded an autoimmune cause. Under repeated treatment with intravenous fluid resuscitation (outpatient treatment), his symptoms resolved and peak CK levels of 44,180 U/L returned to almost normal levels within two weeks. Rhabdomyolysis is a rare, potentially fatal vaccine-induced reaction. Further research is needed to better understand the underlying pathomechanism and to investigate whether subcutaneous injection of vaccines may be able to prevent rhabdomyolysis.https://www.mdpi.com/2076-393X/9/9/956COVID-19vaccineAd26.COV2.Srhabdomyolysismyoglobinuria |
| spellingShingle | Georg Gelbenegger Filippo Cacioppo Christa Firbas Bernd Jilma Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination Vaccines COVID-19 vaccine Ad26.COV2.S rhabdomyolysis myoglobinuria |
| title | Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination |
| title_full | Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination |
| title_fullStr | Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination |
| title_full_unstemmed | Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination |
| title_short | Rhabdomyolysis Following Ad26.COV2.S COVID-19 Vaccination |
| title_sort | rhabdomyolysis following ad26 cov2 s covid 19 vaccination |
| topic | COVID-19 vaccine Ad26.COV2.S rhabdomyolysis myoglobinuria |
| url | https://www.mdpi.com/2076-393X/9/9/956 |
| work_keys_str_mv | AT georggelbenegger rhabdomyolysisfollowingad26cov2scovid19vaccination AT filippocacioppo rhabdomyolysisfollowingad26cov2scovid19vaccination AT christafirbas rhabdomyolysisfollowingad26cov2scovid19vaccination AT berndjilma rhabdomyolysisfollowingad26cov2scovid19vaccination |